Skip to main content
INTS logo

INTS · Intensity Therapeutics, Inc. · Documents

Track INTS — free
$3.07 -0.01 (-0.32%) At close · Nov 16 Play latest call Q3 2026 earnings call transcript
Market Cap
$10.13M
Shares
3.30M
Volume · Nov 16 4555 Avg daily vol (3M) 22.42K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $11.61M 10-K filed Mar 27, 2026 Quarterly report FY2026 Q3 Net loss $3.54M 10-Q filed Nov 5, 2026 Latest results Enrollment Resumes in Two Trials; Cash Stand at $8.5 Million 8-K filed Nov 5, 2026 Earnings call Q3 2026 earnings call Held Nov 5, 2026
2026
Nov 5
Earnings call
Enrollment resumes as capital constrains trial expansion

Intensity Therapeutics resumed patient enrollment in Invincible III and Invincible IV, while capital remained the gating factor for Invincible III activation and enrollment speed. Cash and equivalents were $8.5 million as of September 30, 2026.

5 source passages
Good morning, and welcome to the Intensity Therapeutics third quarter 2026 financial results conference call. In the current year quarter, we resumed new patient enrollment activities in the Invincible III study in a limited number of U.S. sites after pausing new site activations and patient enrollment in March 2025 due to funding constraints. Our clinical trial expenses also included $104,000 for our Phase II Invincible IV study, which also resumed patient enrollment and treatment. So, capital will be the gating factor on how quickly we enroll. As of September 30, 2026, we had cash and cash equivalents of $8.5 million. Open the document at this passage
Nov 5
Current report 8-K
Enrollment Resumes in Two Trials; Cash Stand at $8.5 Million

Intensity Therapeutics reported enrollment resumed in INVINCIBLE-3 and INVINCIBLE-4 during the third quarter of 2026. Cash and cash equivalents were $8.5 million as of September 30, 2026, while third-quarter net loss was $3.5 million.

Financial results
5 source passages
New patient enrollment activities resumed in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study in the third quarter of 2026 New patient enrollment and treatment resumed in the presurgical triple negative breast cancer (“TNBC”) Phase 2 INVINCIBLE-4 Study in the third quarter of 2026 Cash and cash equivalents of $8.5 million as of September 30, 2026 Net loss was $3.5 million for the third quarter of 2026, compared with a net loss of $2.7 million for the third quarter of 2025. SHELTON, Conn., November 5, 2026 – Intensity Therapeutics, Inc. (“Intensity” or “the Company”) (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces third quarter 2026 financial results and provides a business update. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Enrollment resumes as going-concern doubt persists

Intensity Therapeutics resumed INVINCIBLE-3 enrollment in the third quarter of 2026, while INVINCIBLE-4 data showed 71% pCR versus 42% for SOC. Cash was $8.5 million and nine-month net loss was $9.0 million, raising substantial going-concern doubt.

Net loss $3.54M Diluted EPS -$1.09
Read from the MD&A section
8 source passages
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. In July 2024, we initiated and dosed our first patient in a Phase 3 open-label, randomized study (the “INVINCIBLE-3 Study”) testing INT230-6 as a monotherapy compared to the standard of care (“SOC”) drugs in second- and third-line treatment for certain soft tissue sarcoma subtypes. In October 2024, in collaboration with the Swiss Cancer Institute (“SCI”), formerly the Swiss Cancer Group for Clinical Cancer Research (SAKK), we initiated and dosed our first patient in a Phase 2 study (the “INVINCIBLE-4 Study”) to treat patients with localized triple-negative breast cancer. New patient enrollment activities resumed in the third quarter of 2026. Preliminary data from the first 14 patients (seven in each cohort) showed a 71% pCR in patients receiving INT230-6 in Cohort A and a 42% pCR in patients receiving the SOC alone (Cohort B). As of September 30, 2026, our cash and cash equivalents were approximately $8.5 million. We incurred net losses of $9.0 million and $8.6 million for the nine months ended September 30, 2026 and 2025, respectively. As a result, we believe there is substantial doubt about our ability to continue as a going concern. Open the document at this passage
Mar 27
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss $11.61M Diluted EPS -$8.56
Mar 23
Current report 8-K
Other events AI summary on its way
Mar 6
Current report 8-K Events of Mar 5
Other events AI summary on its way
2025
2024
Showing 1–50 of 99 documents
Key facts CIK 1567264 CUSIP 45828J202 13F (30d) 14 filings 14 filers Visit website Investor relations